Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 ...
A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...
Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback